AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14694970 — intervention group
Group type: COMPARATOR
Intervention: Both groups (gel and pessary)
Number of subjects: 115
Study 10649809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 192
Study 10649809 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide
Number of subjects: 192
Study 9335389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2-g treatment group
Number of subjects: 0
Study 9335389 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (quadruple sequential induction therapy)
Number of subjects: 0
Study 9335389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 8254147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 8254147 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 8254147 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and Amitriptyline
Number of subjects: 0
Study 2871486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 291
Study 2871486 — intervention group
Group type: COMPARATOR
Intervention: Control immunosuppressive therapy (azathioprine and prednisone, with or without antilymphocyte globulin)
Number of subjects: 291
Study 31145180 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity double-leg cycling (MCTDL)
Number of subjects: 53
Study 31145180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity double-leg cycling (HITDL)
Number of subjects: 53
Study 31145180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity single-leg cycling (HITSL)
Number of subjects: 53
Study 30129417 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical simvastatin 1% topical solution
Number of subjects: 76
Study 30129417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin 20mg/day
Number of subjects: 76
Study 30129417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 27665525 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (proton pump inhibitor, amoxicillin 1000mg, clarithromycin 500mg or metronidazole 400mg, given twice daily for 7-14 days)
Number of subjects: 485
Study 27665525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (PPI twice daily for 10 days, amoxicillin 1000mg twice daily for the first 5 days, followed by clarithromycin 500mg and metronidazole 400mg twice daily for the subsequent 5 days)
Number of subjects: 485
Study 27665525 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 485
Study 27665525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 485
Study 27665525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 485
Study 25240704 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 199
Study 25240704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 25240704 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 199
Study 22578530 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention for at-risk drinking (BMI-ETOH) among Hispanics with drug dependence
Number of subjects: 1493
Study 19394553 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure bandages (20-30 mm Hg)
Number of subjects: 36
Study 19394553 — intervention group
Group type: COMPARATOR
Intervention: High pressure bandages (44-58 mm Hg)
Number of subjects: 36
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis by dermatopathologists
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of basal cell carcinoma
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of SCC in the actinic keratosis spectrum
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of invasive SCC
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of SCC in situ
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of actinic keratosis
Number of subjects: 0
Study 17482716 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic diagnosis of morphea subtype of basal cell carcinoma
Number of subjects: 0
Study 15302787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sirolimus (24 mg loading dose, 2 mg/d for 7 days)
Number of subjects: 300
Study 15302787 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-dose sirolimus (8 mg loading dose, 2 mg/d for 7 days)
Number of subjects: 300
Study 15302787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 12241774 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 4809
Study 12241774 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 4809
Study 8123267 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium 4 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 1)
Number of subjects: 61
Study 8123267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg i.v., followed by 0.5% to 1.5% enflurane and 67% N2O in O2 (Group 2)
Number of subjects: 61
Study 8123267 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg i.v., followed by propofol 50 to 160 micrograms/kg/min i.v. and 67% N2O in O2 (Group 3)
Number of subjects: 61
Study 8123267 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane for maintenance of anesthesia
Number of subjects: 61
Study 3322358 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg, three times daily for 6 weeks
Number of subjects: 15
Study 3322358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31115667 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised low-intensity cycling for 20 minutes during chemotherapy infusion
Number of subjects: 10
Study 31115667 — intervention group
Group type: COMPARATOR
Intervention: Usual care during chemotherapy infusion
Number of subjects: 10
Study 30305142 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care ART initiation from clinic staff
Number of subjects: 600
Study 30305142 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom report, medical history, brief physical exam, and readiness assessment with TB module
Number of subjects: 600
Study 28770525 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourceful Adolescent Program-Autism Spectrum Disorder (RAP-A-ASD)
Number of subjects: 29
Study 28770525 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study 26600017 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum magnesium (Mg) increase of 0.1 mmol/L
Number of subjects: 365
Study 26600017 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum magnesium (Mg) levels over time
Number of subjects: 365
Study 23329358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy alone
Number of subjects: 28
Study 23329358 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with total body irradiation
Number of subjects: 28
Study 23329358 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (combined)
Number of subjects: 28
Study 23329358 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 21611754 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG ODN 2006
Number of subjects: 30
Study 21611754 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30
Study 18345709 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (270 microg/kg dose)
Number of subjects: 0
Study 18345709 — intervention group
Group type: COMPARATOR
Intervention: Activated prothrombin complex concentrate (aPCC)
Number of subjects: 0
Study 16856619 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of codon 33F mutation
Number of subjects: 772
Study 16856619 — intervention group
Group type: COMPARATOR
Intervention: No mutation 33F
Number of subjects: 772
Study 16856619 — intervention group
Group type: EXPERIMENTAL
Intervention: Codon 33 mutations and polymorphisms
Number of subjects: 772
Study 12762614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy with formocresol
Number of subjects: 80
Study 12762614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpotomy with electrosurgery
Number of subjects: 80
Study 10802132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 47
Study 10802132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 47
Study 9070140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic fluid index and computerised cardiotocography
Number of subjects: 500
Study 9070140 — intervention group
Group type: COMPARATOR
Intervention: Maximum pool depth and computerised cardiotocography
Number of subjects: 500
Study 8451098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 19
Study 8451098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3663564 — intervention group
Group type: EXPERIMENTAL
Intervention: oral nadolol 20 mg once daily
Number of subjects: 22
Study 3663564 — intervention group
Group type: COMPARATOR
Intervention: topical timolol 0.25% twice daily
Number of subjects: 22
Study 29501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie plus numeric sodium MNI
Number of subjects: 0
Study 29501682 — intervention group
Group type: COMPARATOR
Intervention: Calorie MNI only
Number of subjects: 0
Study 29501682 — intervention group
Group type: COMPARATOR
Intervention: Sodium warning symbol
Number of subjects: 0
Study 29501682 — intervention group
Group type: COMPARATOR
Intervention: No MNI
Number of subjects: 0
Study 29501682 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste intuition alone
Number of subjects: 0
Study 28515193 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealthcare
Number of subjects: 1225
Study 28515193 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1225
Study 26624927 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRHa)
Number of subjects: 56
Study 26624927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24467642 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine (RPV)
Number of subjects: 1368
Study 24467642 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 1368
Study 24467642 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine (RPV) and efavirenz (EFV)
Number of subjects: 1368
Study 21875783 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound‐guided transbronchial lung biopsy (EBUS‐TBLB)
Number of subjects: 0
Study 21875783 — intervention group
Group type: COMPARATOR
Intervention: CT‐guided percutaneous needle biopsy (CT‐PNB)
Number of subjects: 0
Study 19478340 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 25
Study 19478340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17945069 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 118
Study 17945069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16146905 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete multivessel treatment
Number of subjects: 69
Study 16146905 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion treatment only
Number of subjects: 69
Study 11327675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dk lenses (etafilcon A, Dk/t = 40) for up to 7 days and 6 nights
Number of subjects: 62
Study 11327675 — intervention group
Group type: COMPARATOR
Intervention: High-Dk lenses (lotrafilcon A, Dk/t = 175) for up to 30 days and nights
Number of subjects: 62
Study 9159721 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 5 mg daily
Number of subjects: 24
Study 9159721 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg daily
Number of subjects: 24
Study 9159721 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 20 mg weekly (10 mg x 2)
Number of subjects: 24
Study 9159721 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg weekly
Number of subjects: 24
Study 8424292 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA, bupivacaine 0.25% (Group 1)
Number of subjects: 48
Study 8424292 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA, bupivacaine 0.5% (Group 2)
Number of subjects: 48
Study 8424292 — intervention group
Group type: COMPARATOR
Intervention: Control without TEA (Group 3)
Number of subjects: 48
Study 8424292 — intervention group
Group type: EXPERIMENTAL
Intervention: LEA, bupivacaine 0.5% (Group 4)
Number of subjects: 48
Study 2462443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelseal aortic bifurcation graft
Number of subjects: 100
Study 2462443 — intervention group
Group type: COMPARATOR
Intervention: Unsealed Dacron
Number of subjects: 100
Study 31785201 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-GIB
Number of subjects: 257
Study 31785201 — intervention group
Group type: COMPARATOR
Intervention: GIB
Number of subjects: 257
Study 28835153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (AWS)
Number of subjects: 11
Study 28835153 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (Macintosh laryngoscope)
Number of subjects: 11
Study 26056856 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised lower limb progressive resistance training programme (twice a week for 12 weeks)
Number of subjects: 36
Study 26056856 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 25592456 — intervention group
Group type: EXPERIMENTAL
Intervention: CCUE group (n=67)
Number of subjects: 130
Study 25592456 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (n=63)
Number of subjects: 130
Study 22985906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (habitual bedtime minus 1.5h)
Number of subjects: 19
Study 22985906 — intervention group
Group type: COMPARATOR
Intervention: Control condition (habitual bedtime)
Number of subjects: 19
Study 20947887 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP followed by gemcitabine
Number of subjects: 202
Study 20947887 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine followed by LV5FU2-CDDP
Number of subjects: 202
Study 20947887 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2-CDDP as first-line treatment
Number of subjects: 202
Study 20947887 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine as first-line treatment
Number of subjects: 202
Study 17767800 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (50 mg of daidzein and genistein)
Number of subjects: 132
Study 17767800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 16977291 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation
Number of subjects: 0
Study 16977291 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation and surgery
Number of subjects: 0
Study 12651635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 30 mg/kg
Number of subjects: 80
Study 12651635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 80
Study 10395156 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting-enhanced methadone detoxification
Number of subjects: 102
Study 10395156 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone detoxification
Number of subjects: 102
Study 8857512 — intervention group
Group type: EXPERIMENTAL
Intervention: High PNG diet (1.52 mg/d of vitamin B-6, 27% PNG)
Number of subjects: 9
Study 8857512 — intervention group
Group type: COMPARATOR
Intervention: Low PNG diet (1.44 mg/d of vitamin B-6, 9% PNG)
Number of subjects: 9
Study 1509190 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (100 mg per day)
Number of subjects: 102
Study 1509190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 1509190 — intervention group
Group type: COMPARATOR
Intervention: Almitrine and Placebo
Number of subjects: 102
Study 6476299 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphin sublingual (0.4 mg.)
Number of subjects: 40
Study 6476299 — intervention group
Group type: COMPARATOR
Intervention: Pentazocin i.m. (30 mg.)
Number of subjects: 40
Study 30474740 — intervention group
Group type: EXPERIMENTAL
Intervention: Team handball training (HG; n=14)
Number of subjects: 26
Study 30474740 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (CG; n=12)
Number of subjects: 26
Study 29937430 — intervention group
Group type: EXPERIMENTAL
Intervention: sotagliflozin 200 mg
Number of subjects: 793
Study 29937430 — intervention group
Group type: EXPERIMENTAL
Intervention: sotagliflozin 400 mg
Number of subjects: 793
Study 29937430 — intervention group
Group type: EXPERIMENTAL
Intervention: sotagliflozin
Number of subjects: 793
Study 29937430 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 793
Study 27085076 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP‐CSBP
Number of subjects: 349
Study 27085076 — intervention group
Group type: COMPARATOR
Intervention: Stan‐CSBP
Number of subjects: 349
Study 24983260 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin flushing protocol
Number of subjects: 0
Study 24983260 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-only flushing protocol
Number of subjects: 0
Study 24983260 — intervention group
Group type: COMPARATOR
Intervention: Flushing protocols (general)
Number of subjects: 0
Study 22128082 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine/methylprednisolone (AZA/MP)
Number of subjects: 87
Study 22128082 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous cyclophosphamide (ivCY)
Number of subjects: 87
Study 21284283 — intervention group
Group type: EXPERIMENTAL
Intervention: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + BPO wash 4%
Number of subjects: 0
Study 21284283 — intervention group
Group type: COMPARATOR
Intervention: CT gel (clindamycin phosphate 7.2% - tretinoin 0.025%) + SFC (nonmedicated soap-free cleanser)
Number of subjects: 0
Study 17272314 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-added bicarbonate solution (90 mg/dl)
Number of subjects: 42
Study 17272314 — intervention group
Group type: COMPARATOR
Intervention: Glucose-free bicarbonate solution
Number of subjects: 42
Study 15121352 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic continuation
Number of subjects: 7
Study 15121352 — intervention group
Group type: COMPARATOR
Intervention: Taper to placebo
Number of subjects: 7
Study 11855050 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture school (8.5 hours)
Number of subjects: 94
Study 11855050 — intervention group
Group type: COMPARATOR
Intervention: Nursing informatics classes (8.5 hours)
Number of subjects: 94
Study 10193252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 163
Study 10193252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 8090312 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in air/O2
Number of subjects: 200
Study 8090312 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane + fentanyl in air/O2
Number of subjects: 200
Study 8090312 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol + fentanyl in N2O/O2
Number of subjects: 200
Study 8090312 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane in N2O/O2
Number of subjects: 200
Study 3192904 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotelon (4 tablets of 50 mg per day for five weeks)
Number of subjects: 100
Study 3192904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 31773485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc glycine chelate (ZnG) at 90 mg Zn/kg
Number of subjects: 810
Study 31773485 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate (ZnS)
Number of subjects: 810
Study 31773485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc supplementation (ZnG and ZnS)
Number of subjects: 810
Study 31773485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 810
Study 31773485 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc glycine chelate (ZnG)
Number of subjects: 810
Study 30213583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid treatment for 8 weeks
Number of subjects: 97
Study 29157592 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 37
Study 29157592 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 37
Study 26164784 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free powder lidocaine delivery system (0.5 mg of lidocaine)
Number of subjects: 535
Study 26164784 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 535
Study 23537980 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (T; n = 120)
Number of subjects: 241
Study 23537980 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C; n = 121)
Number of subjects: 241
Study 21346100 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (3 mg caffeine/kg body weight)
Number of subjects: 16
Study 21346100 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 16
Study 21346100 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 16
Study 19596139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy (IP)
Number of subjects: 342
Study 19596139 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (IV)
Number of subjects: 342
Study 19596139 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125 >35 U/ml
Number of subjects: 342
Study 15848534 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid avoidance (CSAV) regimen
Number of subjects: 109
Study 15848534 — intervention group
Group type: COMPARATOR
Intervention: Control group (CsA, MMF, and CS)
Number of subjects: 109